Compare GSK plc (GSK) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Taskus Inc — how do they compare? GSK plc trades at $46.62 (market cap $91.88B), while Taskus Inc trades at $8.09 (market cap $723.41M). The key difference: GSK plc is far larger — about 127× Taskus Inc's market cap, and GSK plc pays a 3.9% dividend while Taskus Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Taskus Inc for 34 Days on average.
| GSK | TASK | |
|---|---|---|
Market Cap | $91.88B | $723.41M |
Volume | 7,730,529 | 201,303 |
Sector | Health | Technology |
52-Week High | $61.18 | $14.69 |
52-Week Low | $43.24 | $4.57 |
Typical Hold Time | 93 Days | 34 Days |
Enterprise Value | $111.88B | $1.09B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
TaskUs (TASK) trades at $8.06, up 2.15% today, with a bearish technical signal but strong fundamentals. Revenue reached $1.18 billion in 2025, with net income surging to $102.28 million and an 8.75% margin. The stock appears undervalued with a P/E of 6.8 and P/S of 0.6. Recent news highlights AI-driven growth offsetting legacy declines, with Q2 2026 earnings beating estimates.
The outlook is mixed: low valuation and AI expansion offer upside, but technical weakness and margin pressure from labor costs pose risks. Analysts are generally bullish with a $9.33 consensus target, implying 16% upside, though competitive and execution challenges remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
